NCT02207088View on ClinicalTrials.gov

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

December 6, 2016

Study Completion Date

December 6, 2016

Conditions
Chronic Hepatitis CHepatitis C VirusCompensated CirrhosisSevere Renal ImpairmentEnd-stage Renal Disease
Interventions
DRUG

ombitasvir/paritaprevir/ritonavir

tablet

DRUG

dasabuvir

tablet

DRUG

Ribavirin

tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY